Go Deep
Benitec Biopharma Inc.
Benitec Biopharma Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,662 | -8.8 | 1.70 | 0.00 | 821.87 |
| Oct 2026 | 20,798 | -8.5 | 1.63 | 0.00 | 787.11 |
| Oct 2026 | 20,730 | -9.0 | 1.67 | 0.00 | 803.37 |
| Oct 2026 | 20,869 | -8.3 | 1.60 | 0.00 | 768.14 |
| Oct 2026 | 20,370 | -8.5 | 1.65 | 0.00 | 792.66 |
| Oct 2026 | 20,099 | -9.2 | 1.78 | 0.00 | 857.14 |
| Oct 2026 | 20,314 | -8.7 | 1.68 | 0.00 | 803.95 |
| Oct 2026 | 20,096 | -9.0 | 1.74 | 0.00 | 832.53 |
Benitec Biopharma Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -12,809,000.0 | -11,935,000.0 | -11,837,000.0 | -8,965,000.0 |
| EPS | — | -0.2 | -0.3 | -0.2 |
Benitec Biopharma Inc. Revenue & Profit: Last 5 Years
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 75,000.0 | — |
| Net Profit | -45,546,000.0 | -37,917,000.0 | -21,751,000.0 | -19,562,000.0 | — |
| EPS | -1.0 | -1.1 | -1.2 | -14.1 | — |
Benitec Biopharma Inc. Balance Sheet
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Total Assets | 182,623,000.0 | 99,592,000.0 | 52,210,000.0 | 4,464,000.0 | — |
| Total Liabilities | 5,610,000.0 | 2,297,000.0 | 4,962,000.0 | 4,262,000.0 | — |
| Total Equity | 177,013,000.0 | 97,295,000.0 | 47,248,000.0 | 202,000.0 | — |
Owes vs Owns
Benitec Biopharma Inc. owed $0.03 for every $1 it owned in Jun 2026, down from $0.95 in Jun 2023.
| Period | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.03× | 0.02× | 0.10× | 0.95× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Benitec Biopharma Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Jun 2026
Cash & short-term investments 98.5%Other assets 1.0%
How it's funded — Jun 2026
Other liabilities 2.2%Shareholders' equity 96.9%
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 180.0 | 97.7 | 50.9 | 2.5 |
| Receivables | 0.0 | 0.0 | 0.2 | 0.1 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.9 | 1.0 | 0.4 | 0.6 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.8 | 0.8 | 0.7 | 1.3 |
| Liabilities & equity | ||||
| Short-term debt | 0.5 | 0.4 | 0.3 | 0.3 |
| Long-term debt | 0.3 | 0.5 | 0.0 | 0.3 |
| Payables | 0.9 | 0.2 | 1.4 | 1.1 |
| Other liabilities | 3.9 | 1.2 | 3.3 | 2.6 |
| Shareholders' equity | 177.0 | 97.3 | 47.2 | 0.2 |
| Net tangible assets | 177.0 | 97.3 | 47.2 | 0.2 |
Benitec Biopharma Inc. Cash Flow
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Operating Activities | -16,518,000.0 | -23,588,000.0 | -19,403,000.0 | -18,012,000.0 | — |
| Investing Activities | -105,000.0 | -18,000.0 | -179,000.0 | -1,000.0 | — |
| Financing Activities | 98,977,000.0 | 70,485,000.0 | 68,029,000.0 | 16,015,000.0 | — |